Loading stock…

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

6990Market cap $14BPrice $57.5

Country🇨🇳China

SectorHealthcare

IndustryBiotechnology

Develops antibody-drug conjugates and biologics for cancer treatment, spinning out of Kelun Pharmaceutical to chase global oncology markets. Merck bet big here, licensing multiple ADC candidates in deals worth billions, betting China's biotech can out-innovate the West on next-gen cancer drugs.

In Bastion Portfolios?

52W Return-3%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+36%10

Revenue Forecast

Rev CAGR (1y)+35%9

Rev CAGR (3y)+47%10

Rev CAGR (5y)+49%10

Earnings Forecast

EPS Growth Y+1na–

EPS Growth Y+2+230%10

EPS Growth Y+3+125%10

Quality

Margins

EBIT Margin-0%1

Net Income Margin7%5

Free Cash Flow Margin20%8

Debt

Net Debt/EBITDA-44.810

Efficiency

ROE3%2

ROA2%4

Earnings Stability44

GEAR+

Not enough data to calculate the GEAR+ rating.

Value

Price Multiples

P/E Ratio (Forward)3281

P/E Ratio (Forward 3y)651

P/BV17.41

EV Multiples

EV/EBITDA Fwd4201

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield0.5%3

Dividend Yieldna–

Momentum

Short term

1 month return-4%6

3 month return-2%6

YTD return+19%7

Mid term

Price vs 52wHigh78%5

1 year return-19%3

Long term

3 year return+507%10

5 year return+649%10

Risk Shield

Price Risk

Beta0.85

Volatility54%3

Free Cash Flow

Free Cash Flow Margin20%8

Free Cash Flow Yield0.5%3

Quality

ROCE-0%2

Earnings Stability44

Net Debt/EBITDA-44.810

02Growth

Is it actually growing, and how fast?

6990Sichuan Kelun-Biotech Biopharmaceutical Co.

Revenue FY25$294M

GROWTH RATING↗

——

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+36%10

Revenue, next 1Y+35%9

Revenue, next 3Y, CAGR+47%10

Revenue, next 5Y, CAGR+49%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26Ena–

EPS growth, FY27E+230%10

EPS growth, FY28E+125%10

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 36%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 47%/yr over the next 3 years, ahead of most of the market.10/10

Revenue grew 36%/yr over the last 3 years and is set to grow 47%/yr from here.

The runway holds up: revenue is set to grow 49%/yr over five years.10/10

Earnings are set to grow faster than sales (EPS about 125%/yr vs revenue 47%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

Growth is the weak spot here, trailing 100% of companies worldwide.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's speeding up.

03Price Momentum

Is the market behind it right now?

6990Sichuan Kelun-Biotech Biopharmaceutical Co.

Total return Current336%

Price return Current336%

MOMENTUM RATING↗

STRONG67 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%6

3-month return-2%6

YTD return+19%7

MID & LONG-TERM▾SCORE

% of 52-week high78%5

1-year return-19%3

3-year return+507%10

5-year return+649%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +507% over three years and +649% over five, ahead of 90% of the market.

Strong recent results. The stock is outperforming so far this year (+19%).

WATCH

It's down 19% over the past year, now 22% below its 52-week high. That is a touch behind the market.

Returns sit at the market level over the past month (-4%) and over three months (-2%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout.

04Value

Are you paying a fair price for it?

Stop guessing on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

6990Sichuan Kelun-Biotech Biopharmaceutical Co.

Revenue FY25$294M

GROWTH RATING↗

——

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+36%10

Revenue, next 1Y+35%9

Revenue, next 3Y, CAGR+47%10

Revenue, next 5Y, CAGR+49%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26Ena–

EPS growth, FY27E+230%10

EPS growth, FY28E+125%10

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 36%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 47%/yr over the next 3 years, ahead of most of the market.10/10

Revenue grew 36%/yr over the last 3 years and is set to grow 47%/yr from here.

The runway holds up: revenue is set to grow 49%/yr over five years.10/10

Earnings are set to grow faster than sales (EPS about 125%/yr vs revenue 47%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

Growth is the weak spot here, trailing 100% of companies worldwide.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's speeding up.

03Price Momentum

Is the market behind it right now?

6990Sichuan Kelun-Biotech Biopharmaceutical Co.

Total return Current336%

Price return Current336%

MOMENTUM RATING↗

STRONG67 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%6

3-month return-2%6

YTD return+19%7

MID & LONG-TERM▾SCORE

% of 52-week high78%5

1-year return-19%3

3-year return+507%10

5-year return+649%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +507% over three years and +649% over five, ahead of 90% of the market.

Strong recent results. The stock is outperforming so far this year (+19%).

WATCH

It's down 19% over the past year, now 22% below its 52-week high. That is a touch behind the market.

Returns sit at the market level over the past month (-4%) and over three months (-2%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout.

04Value

Are you paying a fair price for it?

Stop guessing on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community